Living with chronic lymphocytic leukemia (CLL) can look very different from one patient to another. Some patients can remain under active surveillance for an extended period without needing treatment, while others eventually develop symptoms or disease changes that make treatment appropriate.
At Wellness Oncology and Hematology, we provide individualized hematology care in Tarzana and West Hills for patients throughout the West San Fernando Valley. CLL care may include regular monitoring, targeted therapies such as BTK or BCL-2 inhibitors, monoclonal antibodies, and other treatments selected according to disease characteristics, symptoms, laboratory findings, previous treatment, and individual circumstances.
Understanding Chronic Lymphocytic Leukemia and Disease Progression
What Happens in Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia is a blood cancer involving abnormal B lymphocytes, a type of white blood cell. These cells can accumulate in the blood, bone marrow, lymph nodes, and other lymphatic tissues. Over time, the abnormal cells can interfere with normal blood cell production and contribute to symptoms or complications.
CLL does not progress at the same rate in every patient. Some individuals have few or no symptoms for an extended period, while others develop progressive disease that eventually requires treatment. This variation is one reason regular hematology follow-up remains an important part of CLL care.
What Does “Watch and Wait” Mean for CLL?
Active surveillance, sometimes called “watch and wait” or observation, is an established approach in which CLL is monitored closely without beginning treatment immediately.
For appropriately selected patients, observation can avoid unnecessary treatment and its potential side effects while the disease remains stable. Monitoring may include blood counts, physical examinations, symptom assessments, and additional testing when clinically appropriate.
A decision to begin treatment is based on evidence that the disease has become active or is progressing in a way that warrants therapy, rather than simply on the fact that CLL has been diagnosed.
For patients who are not experiencing symptoms or other indications for treatment, active surveillance can therefore be an intentional part of CLL management rather than a lack of care.
Also Read: Leukemia: Common Types, Symptoms & Treatment in Southern California: Wellness Oncology & Hematology: Oncologists
Modern Targeted Therapies for CLL
CLL treatment has expanded beyond conventional chemotherapy to include therapies designed to interfere with biological pathways that leukemia cells depend on for survival and growth. These options include BTK inhibitors, BCL-2 inhibitors, and monoclonal antibodies.
The availability of targeted therapies does not mean every patient with CLL should begin treatment. The decision to treat, as well as the medication or combination selected, depends on the characteristics of the disease and the patient’s overall clinical situation.
BTK Inhibitors
Bruton’s tyrosine kinase, or BTK, is involved in signaling that helps B cells survive and function. BTK inhibitors interfere with this signaling pathway and can be used in selected CLL treatment settings.
Examples include acalabrutinib and zanubrutinib. The appropriate medication and treatment duration depend on factors such as disease status, previous treatment, molecular findings, other medical conditions, and potential medication interactions.
Many BTK inhibitors are taken orally, allowing much of the treatment to occur outside an infusion center. Oral treatment still requires regular medical monitoring, however. The hematology team follows treatment response, potential side effects, and possible interactions with other medications.
BCL-2 Inhibitors: Venetoclax
BCL-2 is a protein that helps certain leukemia cells avoid programmed cell death. Venetoclax is a BCL-2 inhibitor that blocks this protein, which can promote the death of CLL cells. It may be used as part of selected treatment regimens for appropriate patients.
One difference between venetoclax and some other targeted approaches is that it can be incorporated into regimens designed for a defined treatment period.
Venetoclax also requires careful treatment initiation. Because the medication can cause leukemia cells to break down rapidly, treatment begins with a managed dose-escalation process intended to reduce the risk of tumor lysis syndrome. The treatment plan and monitoring requirements depend on the patient’s individual circumstances.
Anti-CD20 Monoclonal Antibodies
Monoclonal antibodies are laboratory-produced proteins designed to recognize particular biological targets. Anti-CD20 antibodies such as obinutuzumab and rituximab target B cells expressing CD20 and may be incorporated into selected CLL treatment regimens.
Unlike oral targeted medications, these therapies are administered by infusion. Whether an anti-CD20 antibody is used, and whether it is combined with another targeted therapy, depends on the patient’s disease characteristics and treatment plan.
How CLL Treatment Approaches Differ
Understanding the basic differences among CLL treatment approaches can make discussions with your hematologist easier.
Treatment selection is individualized. Factors such as disease characteristics, molecular and cytogenetic findings, previous treatment, overall health, other medications, treatment goals, and potential short- and long-term side effects can influence which approach is considered.
Living Well With CLL: Long-Term Care and Management
Living with CLL involves more than deciding whether to begin anticancer treatment. Long-term care may include monitoring blood counts and symptoms, managing treatment effects, reducing infection risks, addressing other health conditions, and maintaining quality of life.
Infection Prevention and Immune Health
CLL and some CLL treatments can affect immune function, which makes infection prevention an important part of long-term care.
Vaccination recommendations may differ depending on a patient’s immune status and treatment. Non-live vaccines may be appropriate in many circumstances, although the immune response can be reduced in some patients. Live vaccines may not be appropriate for patients who are significantly immunocompromised.
Patients should review vaccination decisions with their medical team so recommendations can be based on their immune status and current treatment. Fever, persistent infections, or other concerning symptoms should also be discussed promptly with the healthcare team.
Routine Monitoring and Quality of Life
Regular follow-up allows the hematology team to watch for changes in CLL and assess how treatment is being tolerated when therapy is underway. Depending on the individual situation, monitoring may include complete blood counts, physical examinations, symptom review, and additional laboratory or molecular testing.
Quality of life also remains an important part of long-term care. Fatigue, sleep, nutrition, emotional well-being, medication management, and other health conditions can all affect how a patient feels and functions while living with CLL.
What Does the CLL Care Journey Look Like?
CLL management changes according to the status of the disease. Some patients may remain under active surveillance, while others need treatment and ongoing assessment of their response.
Step 1: Hematology Evaluation and Biomarker Testing
The initial evaluation helps establish the current status of the CLL and identify factors that may influence treatment decisions.
Depending on the clinical situation, testing may include cytogenetic and molecular findings such as TP53, del(17p), and IGHV status. These findings can provide important information when the hematology team is determining whether treatment is needed and which therapies may warrant consideration.
Step 2: Individualized Treatment Planning
The hematology team determines whether continued active surveillance is appropriate or whether treatment should begin.
If treatment is indicated, the plan can take into account the biology of the disease, previous therapy, other medical conditions, medication considerations, and the patient’s treatment preferences.
Step 3: Treatment and Side-Effect Management
Depending on the treatment plan, patients may receive oral targeted therapy, intravenous infusion therapy, or a combination.
Regular follow-up helps the care team assess response and identify potential treatment-related effects. Monitoring can also help determine whether the current treatment should continue or whether the plan needs to be adjusted.
Step 4: Long-Term Monitoring
CLL care continues after a treatment decision is made. Ongoing surveillance may include blood counts, assessment of treatment response, symptom review, and monitoring of overall health.
For patients who complete a defined-duration treatment regimen, continued hematology follow-up remains important even when active therapy has ended.
Also Read: What Happens After a Cancer Diagnosis? Understanding Your First Oncology Appointment
CLL Care in Tarzana and West Hills
At Wellness Oncology and Hematology, we provide hematology and oncology care for patients with blood cancers, including CLL. Evaluation may include laboratory testing, review of disease characteristics and molecular findings, previous treatment, current symptoms, and other health considerations.
Our hematology and oncology services include evaluation of blood cancers, targeted treatment approaches, genomic testing, and infusion services.
Our Tarzana and West Hills locations serve patients from Woodland Hills, Encino, and communities throughout the West San Fernando Valley. Depending on the patient’s needs, care may include active surveillance, targeted therapy, infusion treatment, and ongoing monitoring.
Frequently Asked Questions
What Is the Difference Between “Watch and Wait” and Starting Active Treatment for CLL?
“Watch and wait,” also called active surveillance or observation, means monitoring CLL closely without beginning cancer treatment immediately. This approach may be used when the disease is not causing symptoms or other problems that warrant treatment.
Follow-up may include blood tests, physical examinations, symptom review, and additional testing when appropriate. Active treatment may be considered when CLL becomes symptomatic or shows clinically significant progression. Changes in blood counts, significantly enlarged lymph nodes, or symptoms affecting quality of life are among the factors a hematologist may consider.
How Do Modern Targeted Therapies for CLL Differ From Traditional Chemotherapy?
Targeted therapies are designed to interfere with particular biological pathways or cellular characteristics involved in CLL. Examples include BTK inhibitors, BCL-2 inhibitors such as venetoclax, and certain monoclonal antibodies.
Traditional chemotherapy works more broadly against rapidly dividing cells. Targeted therapies work differently, but that does not mean they are free of potential side effects. They still require appropriate medical monitoring and have expanded the treatment options available for patients with CLL.
What Are BTK Inhibitors, and How Long Are They Taken for CLL?
BTK inhibitors are targeted medications that interfere with Bruton’s tyrosine kinase, an enzyme involved in signaling that helps B cells survive and function. Examples used in CLL include acalabrutinib and zanubrutinib, while other BTK inhibitors may have roles in particular treatment settings.
Treatment duration depends on the specific medication and treatment strategy. Some regimens involve ongoing treatment, while certain combination approaches may use defined treatment periods. Your hematologist can determine the appropriate duration based on your CLL, previous treatments, response, side effects, and overall treatment plan.
Can Venetoclax Put CLL Into Complete Remission?
Venetoclax-containing regimens can produce deep responses in CLL and may be used as fixed-duration treatment in appropriately selected patients. However, complete remission is not guaranteed, and treatment response varies among patients.
Treatment goals can include controlling the disease, achieving a deeper response, managing symptoms, and maintaining that response after treatment. Patients should discuss the expected goals, duration, and monitoring plan for a venetoclax-containing regimen with their hematologist rather than assuming that a particular therapy will result in a cure.
What Biomarker or Cytogenetic Tests May Be Used Before CLL Treatment?
Testing is individualized, but certain molecular and cytogenetic findings can influence CLL treatment planning. Depending on the clinical situation, evaluation may include fluorescence in situ hybridization (FISH), TP53 variant analysis, and IGHV testing.
FISH may evaluate abnormalities including del(17p), del(11q), del(13q), and trisomy 12. Other evaluation may include a complete blood count, chemistry testing, immunoglobulin levels, and selected infectious-disease testing when appropriate. A hematologist determines which tests are relevant based on the diagnosis, current disease status, previous treatment, and planned therapy.
How Do I Schedule a CLL Consultation at Wellness Oncology and Hematology?
You can request a consultation with our hematology and oncology team at our Tarzana or West Hills location. If available, bring relevant laboratory or pathology reports, imaging reports, your current medication list, and records from previous CLL treatment.
These records can help our team understand the history and current status of your CLL, determine whether additional testing may be needed, and discuss appropriate monitoring or treatment options.
Discuss Your CLL Care With a Hematologist
A CLL diagnosis does not automatically mean treatment needs to begin immediately. Some patients can remain under active surveillance, while others may eventually need treatment based on symptoms, blood counts, disease progression, molecular findings, and other clinical factors.
At Wellness Oncology and Hematology, we provide individualized CLL evaluation and care in Tarzana and West Hills for patients throughout the West San Fernando Valley. Schedule a consultation with our hematology team to review your diagnosis, current disease status, previous treatment, and whether continued monitoring or treatment may be appropriate.
This article provides general educational information and is not a substitute for individualized medical advice. Diagnosis, treatment candidacy, treatment duration, and outcomes vary. Consult a qualified hematologist-oncologist for an individualized evaluation and treatment plan.